



**Karolinska  
Institutet**

# Prostate Cancer Genetics: Today and tomorrow

Henrik Grönberg


Professor Cancer Epidemiology, Deputy Chair

Department of Medical Epidemiology and Biostatistics ( MEB)

Karolinska Institutet, Stockholm

**IMPACT-Atanta**

# Familial aggregation of prostate cancer



(Meta analysis, Johns and Houlston 2003)

**Genes**


**Environment**




**Karolinska  
Institutet**



# Familial aggregation is due to genetics




Lichtenstein et al 2000



# Different scenarios how germline variation effects the risk of prostate cancer

1. Rare variant                      High Risk ( RR>5)
    - Family studies ( BRCA1/2 )
  2. Rare variant                      Low risk ( RR 1.2-2)
    - Sequencing/association studies
  3. Common variant                  Low risk (RR 1.2-2)
    - Association studies/Genome Wide Association studies (GWAS)
-

# 1. Rare variant High risk



Swedish family with BRCA2 mutation

UNCOMMON, is going to account for  $< 0.1\%$

## 2. Rare Variant

## Low Risk (OR= 1.1-2.5)

- Breast cancer
    - CHEK2, 1100delC mutation , 1.9% of all cases and 0.7% in controls which OR=2.3 ( CHEK2 consortium 2004)
    - ATM gene, OR=2.3 if combining all truncating mutations together (2,7% among cases and 0.4% among controls (Renwick 2006)
  - This is difficult and time consuming
-



### 3. Common variant Low risk (RR=1.2-1.7)

- Several good examples in other complex diseases e.g. asthma, osteoporosis, stroke, AMI the last year
  - Three possibilities to identify these variants
    - Direct genetic association studies in candidate genes and pathways
    - Linkage in family studies, fine mapping by association in case-control studies
    - Genome wide SNP scan ( 300.000-500.000 SNPs)
      - **BREAKTHROUGH LAST YEAR**
      - Chromosome 8 and 17 in prostate cancer
-

---

## A common variant associated with prostate cancer in European and African populations

Laufey T Amundadottir<sup>1,12</sup>, Patrick Sulem<sup>1,12</sup>, Julius Gudmundsson<sup>1,12</sup>, Agnar Helgason<sup>1</sup>, Adam Baker<sup>1</sup>, Bjarni A Agnarsson<sup>2</sup>, Asgeir Sigurdsson<sup>1</sup>, Kristrun R Benediktsdottir<sup>2</sup>, Jean-Baptiste Cazier<sup>1</sup>, Jesus Sainz<sup>1</sup>, Margret Jakobsdottir<sup>1</sup>, Jelena Kostic<sup>1</sup>, Droplaug N Magnusdottir<sup>1</sup>, Shyamali Ghosh<sup>1</sup>, Kari Agnarsson<sup>1</sup>, Birgitta Birgisdottir<sup>1</sup>, Louise Le Roux<sup>1</sup>, Adalheidur Olafsdottir<sup>1</sup>, Thorarinn Blondal<sup>1</sup>, Margret Andresdottir<sup>1</sup>, Olafia Svandis Gretarsdottir<sup>1</sup>, Jon T Bergthorsson<sup>1</sup>, Daniel Gudbjartsson<sup>1</sup>, Arnaldur Gylfason<sup>1</sup>, Gudmar Thorleifsson<sup>1</sup>, Andrei Manolescu<sup>1</sup>, Kristleifur Kristjansson<sup>1</sup>, Gudmundur Geirsson<sup>3</sup>, Helgi Isaksson<sup>2</sup>, Julie Douglas<sup>4</sup>, Jan-Erik Johansson<sup>5</sup>, Katarina Bälter<sup>6</sup>, Fredrik Wildund<sup>6</sup>, James E Montie<sup>7</sup>, Xiaoying Yu<sup>8</sup>, Brian K Suarez<sup>9</sup>, Carole Ober<sup>10</sup>, Kathleen A Cooney<sup>7,11</sup>, Henrik Gronberg<sup>6</sup>, William J Catalona<sup>8</sup>, Gudmundur V Einarnsson<sup>3</sup>, Rosa B Barkardottir<sup>2</sup>, Jeffrey R Gulcher<sup>1</sup>, Augustine Kong<sup>1</sup>, Unnur Thorsteinsdottir<sup>1</sup> & Kari Stefansson<sup>1</sup>

Common genetic variant identified on chromosome 8q24 associated with prostate cancer

---

# Genetic association studies


*Jianfeng Xu, M.D., Dr.PH*

*Professor of Public Health and Cancer Biology  
Director, Program for Genetic and Molecular Epidemiology of Cancer  
Associate Director, Center for Human Genomics  
Wake Forest University School of Medicine*

# What causes genetic association?

---

- Low degree of recombination between two loci
- A genetic association exists between two loci
  - If they are close to each other on a same chromosome, or
  - If the population is “young” or has experienced recent admixture



# Basic assumptions of genetic association studies

---

- A disease has genetic susceptibility
  - As shown by family studies, twin studies, segregation studies

# Basic assumptions of genetic association studies

---

- A disease has genetic susceptibility
  - As shown by family studies, twin studies, segregation studies
- The genetic susceptibility is caused by inherited variants
  - Point mutation (SNPs), indel, large-scale deletions and insertions (CNPs)

# Basic assumptions of genetic association studies

---

- A disease (or drug response) has genetic susceptibility
  - As shown by family studies, twin studies, segregation studies
- The genetic susceptibility is caused by inherited variants
  - Point mutation (SNPs), indel, large-scale deletions and insertions (CNPs)
- Genetic markers are located near the causal variants (coverage)
  - Millions of SNPs are mapped and characterized

# Basic assumptions of genetic association studies

---

- A disease (or drug response) has genetic susceptibility
  - As shown by family studies, twin studies, segregation studies
- The genetic susceptibility is caused by inherited variants
  - Point mutation (SNPs), indel, large-scale deletions and insertions (CNPs)
- Genetic markers are located near the causal variants (coverage)
  - Millions of SNPs are mapped and characterized
- Large enough study population (sample size)
  - Depends on the effect of risk variants



# Properties of associated genetic variants

---

- If associated with the disease, inherited variants or nearby markers are expected to have two properties:
  - They will have a higher frequency in cases than in controls
    - Can be detected using a case-control study design
  - They are more likely to be transmitted to affected offspring
    - Can be detected using family-based study design

# So, in an ideal world ...

---

- We would have enough \$\$\$\$\$\$\$\$ (funding)
  - We could identify very large study populations
  - We could genotype all the variants
  - We would find the risk variants easily !!!

# The problem is, in real life ....

---

- We don't have enough \$\$\$\$\$\$\$\$ (funding)
- But we can be smarter by...
  - carefully considering the study design
    - Study populations enriched for specific genetic risk factors
    - Multiple stages
  - efficiently choosing variants to be genotyped
    - Tagging SNPs, discovery vs. confirmation
- We can still find them and characterize them !!!!

# Issues in genetic association studies

---


- Power
  - OR, MAF, sample size, Type I error, Quanto
- Choice of study populations
  - homogeneous phenotypes
- Choice of SNPs
  - LD, block, tagging SNPs, candidate gene, pathway, and genome-wide
- Choice of analysis
  - Single SNP, haplotype analysis, and imputation
- False positive and false negative
  - multiple tests, population stratification, small effect
- Interaction
  - gene-gene, gene-environment, gene-gene-environment

# Study populations

---

- Familial cases
- Aggressive prostate cancer
- Homogeneous population

# SNPs are not independent



# Haplotype blocks

---

## ■ Haplotype blocks

- Sizable regions over which there is little historical recombination
- All (or nearly all) pairs of markers are in “strong LD”
- “Strong LD” if upper 95% CI of  $D'$  is  $> 0.98$  and the lower 95% CI is  $> 0.7$
- “Strong evidence for historical recombination” if upper 95% CI of  $D'$  is  $< 0.9$

## ■ Haplotype tagging SNPs (htSNPs)

- Limited haplotypes within haplotype blocks ( $\ll 2^n$ )
- htSNPs are selected to capture the majority of haplotypes within blocks
- Significantly decrease the number of SNPs need to be genotyped

# Bins and tag SNPs (tSNPs)

---

## ■ Bins

- SNPs can be “binned” into groups of loci that are highly correlated with one another by the measurement of pair-wise  $r^2$

## ■ Tag SNPs (tSNPs)

- tSNPs is selected from each bin, which exceeds the pre-defined threshold  $r^2$  with any other site within the bin
- Relatively easy to calculate and do not assume haplotype blocks



# Strategies for association analysis

---

- Single SNP analysis using pre-specified genetic models
  - Allele test
  - 2 x 3 table (2-df)
  - Additive model (1-df), and test for additivity
  - All possible genetic models
- Haplotype analysis
  - Two-marker and three-marker slide
  - Multi-marker
  - Within haplotype block
  - Between two recombination hot spots
  - Imputation

# Correction for multiple tests

---

- Bonferroni correction -- stringent
- Effective number of tests -- take LD into account
- Bayesian approach -- take *a priori* into account, (e.g. FPRP)
- Permutation Procedures -- permute case-control status

# Population stratification

---

- Genomic control
- Structure (STRUCTURE)
- Principal component analysis (EIGENSTRAT)
  - Identify several eigenvectors (ancestries or geographic regions)
  - Adjust genotypes and phenotypes along each eigenvector
  - Compute association statistics using adjusted genotypes and phenotypes
  - No need for AIMs

# Methods for assessing gene-gene interactions

---

- Gene-gene interaction is common
  - Biological relevance
  - May attribute to false negative
- Interaction with main effect
  - Logistic regression, cumulative effect
- Interaction without main effect: data mining
  - Classification and recursive tree (CART)
  - Multifactor Dimensionality Reduction (MDR)
  - Support vector machine (SVM)

# Genome-wide association

---

- Consider costs, false negatives, and false positives
  - Platform: coverage in different ethnic groups, and cost
  - Multi-stages: power and false positives
  - Analytical approach: false positives and false negatives

# Summary

---

- Genetic association studies are powerful
- There are many practical issues in genetic association studies
- The impact of these issues can be minimized by a well-designed study

# How can we use these genetic markers in the future?

1. Insight in to new mechanisms in prostate cancer development
    - New treatments
  2. Translation to direct patient care
    - Prediction of risk
      - How can a 1,3 risk have any impact on identifying men at high risk of prostate cancer??????
    - Modification of life style
    - Prognostic markers
-